Excellent results in a transformational year
We continue to extend the platform to achieve our aspirational target of mid-teen revenue growth between 2009 and 2015.

Core product sales ($'M)

  

Total revenue ($'M)

  

Year-on-year product growth ($'M)
Core product sales   Revenue growth   Core product sales growth
  • Our core products are the foundation of our future growth.
  • This is one of our most significant Key Performance Indicators ('KPIs').
 
  • In the year in which our historically largest drug, the blockbuster ADDERALL XR, faced generic competition, our total revenues of $3 billion in 2009 were in line with the $3 billion we recorded in 2008.
  
  • Growth is broadly based across the core portfolio.
 

Core product sales growth
(excluding ADDERALL XR)

  

Revenue from ex-US markets* (%)

  

EBITDA ($'M)
(Earnings Before Interest Tax Depreciation and Amortization)
Core product sales growth   Revenue growth from ex-US markets* (%)   EBITDA
  • Our core products are now driving Shire's growth.
  
  • We have a clear objective to grow our business internationally and our KPIs for this is the percentage of sales generated outside the US.
  • Our business is becoming increasingly international.
  
  • Our KPIs for profitability and a key driver of our Return on Invested Capital ('ROIC') is the growth of EBITDA.
  • We delivered a strong EBITDA and earnings performance despite the loss of ADDERALL XR.
 

2009 cashflow ($'M)

        
2009 cashflow ($M)        
  • Our strong cash generation has supported continued investment in our business.